Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccineArchived
The findings from Kreimer et al. need to be confirmed by other studies and require longer-term follow-up.
Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S; for the CVT Vaccine Group. J Natl Cancer Inst. 2011 Sep 9. [Epub ahead of print]
Three-dose regimens for human papillomavirus (HPV) vaccines are expensive and difficult to complete, especially in settings where the need for cervical cancer prevention is greatest. The findings from Kreimer et al. need to be confirmed by other studies and require longer-term follow-up. However, if a one- or two-dose regimen of HPV vaccination does in fact elicit a good and durable immune response, these findings will have a great impact on costs and strategies for HPV vaccination programmes throughout Europe.
OECD highlights the progress made in laboratory systems in the EU/EEA since the implementation of EULabCap
11 Dec 2018 - The OECD report ‘Health at a Glance: Europe 2018’ summarises the EULabCap indicator results in the chapter on public health laboratory capacity to control infectious disease threats.
Conclusions of the eighteenth IHR Emergency Committee do not change the ECDC risk assessment for Europe concerning polio
26 Sep 2018 - Statement of the Eighteenth IHR Emergency Committee Regarding the International Spread of Poliovirus, 15 August 2018
ECDC comment: European Commission updates communicable disease surveillance list - Lyme neuroborreliosis now under EU/EEA surveillance
2 Aug 2018 - ECDC will start monitoring disease distribution in the EU and collecting EU data through the epidemiological surveillance network comprising the European Commission, ECDC and national authorities for epidemiological surveillance.